Gilead Sciences, Inc. $GILD Shares Bought by Trust Co. of Vermont

Trust Co. of Vermont grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% in the second quarter, Holdings Channel.com reports. The fund owned 11,976 shares of the biopharmaceutical company’s stock after buying an additional 320 shares during the quarter. Trust Co. of Vermont’s holdings in Gilead Sciences were worth $1,328,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of GILD. Vanguard Group Inc. raised its stake in Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Gilead Sciences by 12.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after purchasing an additional 1,520,809 shares during the period. Nuveen LLC acquired a new stake in Gilead Sciences during the 1st quarter valued at $620,415,000. Finally, National Pension Service raised its stake in Gilead Sciences by 6.9% during the 1st quarter. National Pension Service now owns 3,473,373 shares of the biopharmaceutical company’s stock valued at $389,191,000 after purchasing an additional 223,171 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.1%

Gilead Sciences stock opened at $111.15 on Thursday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The company has a market capitalization of $137.92 billion, a price-to-earnings ratio of 22.14, a PEG ratio of 0.75 and a beta of 0.34. Gilead Sciences, Inc. has a one year low of $83.10 and a one year high of $121.83. The company’s fifty day moving average price is $114.47 and its two-hundred day moving average price is $109.92.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the prior year, the business posted $2.01 earnings per share. The business’s quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio is 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the sale, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer owned 591,203 shares of the company’s stock, valued at $66,013,726.98. This trade represents a 1.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock worth $9,402,130 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on GILD shares. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a research note on Tuesday, August 19th. Rothschild & Co Redburn upped their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Finally, Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research note on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.